Nikhil I. Khushalani, MD

Nikhil I. Khushalani, MD, discusses outcomes of the HBI-8000-303 trial of a new combination in frontline advanced melanoma.

Nikhil I. Khushalani, MD, discusses the rationale for combining nivolumab with bempegaldesleukin for the treatment of patients with newly diagnosed, unresectable or metastatic melanoma in a randomized, open-label phase III trial.